Wearable cardiac sensor gets CE approval
- 30 September 2009
An advanced new wearable wireless patient monitoring system has received CE mark approval, allowing it to be sold in Europe.
Called the AVIVO mobile patient management system, the system developed by Corventis is designed to enable early detection, prevention and treatment of cardiovascular conditions.
The AVIVO monitoring system allows a patient’s clinician to evaluate physiological changes and monitor signs of cardiac irregularities in patients away from the hospital.
The mobile patient management system was specifically designed to provide focused insight into the cardiac health status of patients, such as those suffering from heart failure. The system combines a patient-friendly PiiX wearable sensor with advanced computer algorithms; global wireless capabilities; and a robust web-based infrastructure.
The wireless design of the senor is intended to encourage continuous wear, even while showering or sleeping. Data collection and transmission is fully automated.
The PiiX sensor automatically collects physiological information and wirelessly transmits the data from the patient to Corventis for further analysis and presentation on a secure website.
Physiological trends that can be monitored include: heart rate, heart rate variability, respiratory rate, fluid status, activity and posture are captured and automatically transmitted for personalized review by healthcare professionals.
Clinicians are also provided actionable information when an irregularity in the patient’s cardiac rhythm occurs, helping to further diagnose potential health risks remotely from anywhere across the globe.
"Corventis is advancing healthcare worldwide, and the CE mark for the AVIVO Mobile Patient Management System is one additional milestone in our efforts to deliver on this promise," said Ed Manicka, president and CEO of Corventis. The system has already obtained FDA clearance in the US.
Some 15m patients in Europe are estimated to suffer from chronic cardiac conditions. It is estimated that the condition is responsible for approximately 5% of all acute medical admissions in Europe.
Link
